The Eclipsys™ Platform: The key to rapidly developing the next generation of bifunctional small molecule degraders
Amphista’s proprietary Eclipsys™ Drug Development Platform underpins the identification of new TPD mechanisms combined with rapid optimization of innovative, differentiated and highly versatile bifunctional TPD therapies.
Expanding therapeutic application
Amphista’s small molecule degrading therapeutics are designed for the potential to target a broad range of diseases in oncology, immunology, CNS disorders and other areas, including many serious diseases that are not readily addressable with initial TPD approaches.
Amphista’s mechanisms are applicable to the degradation of proteins including nuclear, cytosolic and membrane-associated targets, enzymes, epigenetic factors and other classes.
Reduced risk of tumor resistance
In the treatment of both solid and hematological tumors, TPD therapies have shown encouraging results. These positive findings have been mitigated by evidence that tumor cells are able to nullify the mechanisms of these earlier generation therapies, leading to tumor resistance and limited efficacy benefit.
Amphista’s degrading mechanisms incorporate proteins that are also required for tumor cell growth, meaning tumors cannot easily modify the function of these proteins without compromising their own growth. As a result, drugs developed based on Amphista’s novel degrading mechanisms have the potential to reduce the risk of resistance with more durable antitumor responses.
Improved druglike properties
Amphista’s novel mechanistic approach and chemistry-led strategy support development of TPD medicines with better druglike properties, delivering oral bioavailability and efficient tissue penetration, including into the CNS, and expand the scope for development of best-in-class medicines that can successfully target a wide range of challenging diseases.
